Orion - Company Announcement

150,000 Orion A-shares converted into B-shares

ORION CORPORATION        STOCK EXCHANGE RELEASE 25 OCTOBER 2013 at 9.20 a.m.
EEST


In accordance with Section 3 of the Articles of Association of Orion
Corporation, 150,000 A-shares have been converted into 150,000  B-shares. The
conversion has been entered into the Trade Register on 25 October 2013.

The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 42,022,816 A-shares and  99,235,012 B-shares.



Orion Corporation



Olli Huotari               Jari Karlson
SVP, Corporate Functions   CFO







Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1738184]